The aim of this letter is to focus on the survival of patients treated with nivolumab and cabozantinib according to prior first-line TKI. We used data from CheckMate 025 and METEOR for a subsequent subgroup analysis
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis
Roviello, Giandomenico
;Generali, Daniele
2017-01-01
Abstract
The aim of this letter is to focus on the survival of patients treated with nivolumab and cabozantinib according to prior first-line TKI. We used data from CheckMate 025 and METEOR for a subsequent subgroup analysisFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Roviello G, TKI MRCC treated with Nivolumab or Cabozantinib.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Digital Rights Management non definito
Dimensione
432.36 kB
Formato
Adobe PDF
|
432.36 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Roviello European Urology.pdf
Open Access dal 31/07/2018
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Creative commons
Dimensione
366.71 kB
Formato
Adobe PDF
|
366.71 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
